Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Seagen Inc.
At ESMO, data showed overall response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.
A number of new medicines are moving closer to the EU market after the European Medicines Agency recommended in favor of their approval.
Phase III sub-analyses presented at ESMO show the drug providing a survival benefit in a complex subpopulation, as well as improvements to quality of life.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Alpine Biosciences
- Oncothyreon, Inc.
- Cascadian Therapeutics, Inc.
- Seattle Genetics, Inc.